MedTrace Logo

VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate

NCT01777217 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2015-01-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if Vesicare (Solifenacin succinate) is effective in treating over-active bladder symptoms during radiation therapy of the prostate.

Conditions

  • Over-Active Bladder

Interventions

DRUG

Solifenacin succinate

IGRT with VESIcare

DRUG

Placebo

IGRT with placebo

Sponsors & Collaborators

  • Astellas Pharma US, Inc.

    collaborator INDUSTRY

  • Advanced Research Network

    lead INDUSTRY

Principal Investigators

  • Sanjay Mehta, M.D. · Century Cancer Centers

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01777217 on ClinicalTrials.gov